Egetis Therapeutics asks for hugs to increase disease awareness of MCT8 deficiency
February 24, 2022
Stockholm, Sweden, February 24, 2022 – Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) today launched #MCT8Hugs – a global, online initiative to drive awareness of MCT8 deficiency.
MCT8 deficiency is a rare and life-shortening genetic disease, causing serious consequences such as severely impaired neurocognitive development and motor function. In most of those affected, this results in an inability to maintain head control, sit independently and walk. In addition, MCT8 deficiency is associated with a state of chronic thyrotoxicosis manifested by severe underweight, muscle wasting and cardiovascular abnormalities. The disease only affects males, and the first symptoms usually emerge within the first months after birth. While rare, there is a universal need to improve the recognition, understanding and diagnosis of this devastating disease.
